NASDAQ:ANIK Anika Therapeutics Q3 2026 Earnings Date & Estimates $21.33 -0.09 (-0.42%) As of 01:02 PM Eastern This is a fair market value price provided by Massive. Learn more. Anika Therapeutics is estimated to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 6, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Anika Therapeutics in Q3 2026Anika Therapeutics is expected to post earnings of $0.42 per share on revenue of $29.44 million. In the same quarter a year earlier Anika Therapeutics reported $0.04 per share on revenue of $27.82 million. Anika Therapeutics last reported on July 29, 2026, posting $0.42 per share and beating the $0.03 consensus estimate. Anika Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.42Expected Revenue$29.44 millionPrior-Year EPS$0.04Prior-Year Revenue$27.82 millionExpected EPS Growth+950.0%Expected Revenue Growth+5.8%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.42 (Beat by +$0.39)Last Quarter Revenue$32.61 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Anika Therapeutics Q3 2026 Earnings FAQ When does Anika Therapeutics report Q3 2026 earnings? Anika Therapeutics (NASDAQ:ANIK) is estimated to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Anika Therapeutics' Q3 2026 earnings call? Anika Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Anika Therapeutics? Analysts expect Anika Therapeutics to post earnings of $0.42 per share for Q3 2026. How much revenue is Anika Therapeutics expected to report? The consensus revenue estimate for Anika Therapeutics is $29.44 million for Q3 2026. Anika Therapeutics Earnings HeadlinesAnika Therapeutics (NASDAQ:ANIK) Share Price Crosses Above 200 Day Moving Average - Here's What HappenedOctober 24 at 3:01 AM | americanbankingnews.comAnika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026October 22, 2026 | globenewswire.com“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 yearsDr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors.October 26 at 1:00 AM | Weiss Ratings (Ad)Critical Comparison: Anika Therapeutics (NASDAQ:ANIK) and ADMA Biologics (NASDAQ:ADMA)October 19, 2026 | americanbankingnews.comAnika Therapeutics (NASDAQ:ANIK) Shares Break Above Two Hundred Day Moving Average - What's Next?October 16, 2026 | americanbankingnews.comAnika (ANIK) Q2 2026 Earnings Call TranscriptAugust 8, 2026 | finance.yahoo.comSee More Anika Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anika Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anika Therapeutics and other key companies, straight to your email. Email Address About Anika TherapeuticsAnika Therapeutics (NASDAQ:ANIK), Inc. develops, manufactures and commercializes therapeutic products designed to support tissue protection, healing and repair. The company focuses primarily on orthopedics, with products based in part on hyaluronic acid, a naturally occurring substance found in connective tissue and joint fluid. Anika’s orthopedic portfolio includes Monovisc and Orthovisc, viscosupplementation products used to help relieve pain associated with osteoarthritis of the knee, as well as Cingal, which combines hyaluronic acid with a corticosteroid. The company also offers Tactoset, an injectable bone void filler intended for use in orthopedic procedures. Its broader product offerings have included solutions for surgical, wound-care and other medical applications. Founded in 1983, Anika serves healthcare providers and patients in the United States and international markets through direct commercial operations and distribution partners. The company is headquartered in Bedford, Massachusetts, and has built its business around developing and commercializing medical products that use its expertise in hyaluronic acid and other biomaterials.View Anika Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Anthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure GiantsBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big CatalystsMarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline3 Companies With Room to Pass on Costs to Manage InflationNewmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story Upcoming Earnings Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Baker Hughes (10/27/2026)ONEOK (10/27/2026)Robinhood Markets (10/27/2026)HSBC (10/27/2026)S&P Global (10/27/2026)Visa (10/27/2026)HCA Healthcare (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
